
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species
Gabriele Bianco, Matteo Boattini, Sara Comini, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 3, pp. 559-566
Closed Access | Times Cited: 15
Gabriele Bianco, Matteo Boattini, Sara Comini, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 3, pp. 559-566
Closed Access | Times Cited: 15
Showing 15 citing articles:
Cefiderocol susceptibility testing: the challenge of disc diffusion
Katy Jeannot, Laurent Dortet
Clinical Microbiology and Infection (2025)
Closed Access | Times Cited: 2
Katy Jeannot, Laurent Dortet
Clinical Microbiology and Infection (2025)
Closed Access | Times Cited: 2
Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy
Jacob W. Snowdin, Nicholas J. Mercuro, Michael P. Madaio, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Jacob W. Snowdin, Nicholas J. Mercuro, Michael P. Madaio, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains
Vincent Jean-Pierre, Pauline Sorlin, Alix Pantel, et al.
Annals of Clinical Microbiology and Antimicrobials (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Vincent Jean-Pierre, Pauline Sorlin, Alix Pantel, et al.
Annals of Clinical Microbiology and Antimicrobials (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Clinical and microbiological features of positive blood culture episodes caused by non-fermenting gram-negative bacilli other than Pseudomonas and Acinetobacter species (2020–2023)
Roberto Casale, Matteo Boattini, Sara Comini, et al.
Infection (2024)
Open Access | Times Cited: 4
Roberto Casale, Matteo Boattini, Sara Comini, et al.
Infection (2024)
Open Access | Times Cited: 4
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?—right to reply—authors’ response
Ioannis Baltas, Trupti Patel, A Soares
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Ioannis Baltas, Trupti Patel, A Soares
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Comment on: Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
Christopher Longshaw, Boudewijn L DeJonge, Yoshinori Yamano
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Christopher Longshaw, Boudewijn L DeJonge, Yoshinori Yamano
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Comment on: Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
Timothy M. Rawson, Maxwell Al-Hassan, Ilona Brzeska-Trafny, et al.
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Timothy M. Rawson, Maxwell Al-Hassan, Ilona Brzeska-Trafny, et al.
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?—authors’ response
Ioannis Baltas, Trupti Patel, A Soares
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Ioannis Baltas, Trupti Patel, A Soares
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
Issues with Cefiderocol Testing: Comparing Commercial Methods to Broth Microdilution in Iron-Depleted Medium—Analyses of the Performances, ATU, and Trailing Effect According to EUCAST Initial and Revised Interpretation Criteria
Stefano Stracquadanio, Alice Nicolosi, Andrea Marıno, et al.
Diagnostics (2024) Vol. 14, Iss. 20, pp. 2318-2318
Open Access | Times Cited: 3
Stefano Stracquadanio, Alice Nicolosi, Andrea Marıno, et al.
Diagnostics (2024) Vol. 14, Iss. 20, pp. 2318-2318
Open Access | Times Cited: 3
Real-world performance of susceptibility testing for cefiderocol: insights from a prospective multicentre study on Gram-negative bacteria
Álvaro Irigoyen, Azahara Ocaña, Rosa Sánchez-Mayoral, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 5
Open Access | Times Cited: 3
Álvaro Irigoyen, Azahara Ocaña, Rosa Sánchez-Mayoral, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 5
Open Access | Times Cited: 3
Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus
Vincent Jean-Pierre, Pauline Sorlin, Katy Jeannot, et al.
Annals of Clinical Microbiology and Antimicrobials (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Vincent Jean-Pierre, Pauline Sorlin, Katy Jeannot, et al.
Annals of Clinical Microbiology and Antimicrobials (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Cefiderocol – An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing
Małgorzata Brauncajs, Filip Bielec, Anna Macieja, et al.
Advances in Medical Sciences (2024) Vol. 69, Iss. 2, pp. 256-263
Open Access | Times Cited: 1
Małgorzata Brauncajs, Filip Bielec, Anna Macieja, et al.
Advances in Medical Sciences (2024) Vol. 69, Iss. 2, pp. 256-263
Open Access | Times Cited: 1
Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint
Julien Massol, Aurélien Dinh, Katy Jeannot, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 38, pp. 140-145
Open Access | Times Cited: 1
Julien Massol, Aurélien Dinh, Katy Jeannot, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 38, pp. 140-145
Open Access | Times Cited: 1
Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant Pseudomonas aeruginosa Strains: Influence of Bacterial Inoculum
Celia García-Rivera, Antonia Sánchez-Bautista, Mónica Parra-Grande, et al.
Antibiotics (2024) Vol. 13, Iss. 7, pp. 663-663
Open Access
Celia García-Rivera, Antonia Sánchez-Bautista, Mónica Parra-Grande, et al.
Antibiotics (2024) Vol. 13, Iss. 7, pp. 663-663
Open Access
Cefiderocol susceptibility of 146 Stenotrophomonas maltophilia strains clinically isolated from blood in two Japanese hospitals over a 10-year period
Takashi Sakoh, Emiko Miyajima, Yusuke Endo, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024)
Closed Access
Takashi Sakoh, Emiko Miyajima, Yusuke Endo, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024)
Closed Access